Evidence and Mechanisms of Fat Depletion in Cancer

The majority of cancer patients experience wasting characterized by muscle loss with or without fat loss. In human and animal models of cancer, body composition assessment and morphological analysis reveals adipose atrophy and presence of smaller adipocytes. Fat loss is associated with reduced quali...

Full description

Bibliographic Details
Main Authors: Maryam Ebadi, Vera C. Mazurak
Format: Article
Language:English
Published: MDPI AG 2014-11-01
Series:Nutrients
Subjects:
Online Access:http://www.mdpi.com/2072-6643/6/11/5280
id doaj-a5aa9b4dd7b744e298bef7c9aacfec9e
record_format Article
spelling doaj-a5aa9b4dd7b744e298bef7c9aacfec9e2020-11-24T22:22:24ZengMDPI AGNutrients2072-66432014-11-016115280529710.3390/nu6115280nu6115280Evidence and Mechanisms of Fat Depletion in CancerMaryam Ebadi0Vera C. Mazurak1Division of Human Nutrition, Department of Agricultural, Food and Nutritional Science, University of Alberta, 4-002 Li Ka Shing Centre for Health Research Innovation, Edmonton, AB T6G 2E1, CanadaDivision of Human Nutrition, Department of Agricultural, Food and Nutritional Science, University of Alberta, 4-002 Li Ka Shing Centre for Health Research Innovation, Edmonton, AB T6G 2E1, CanadaThe majority of cancer patients experience wasting characterized by muscle loss with or without fat loss. In human and animal models of cancer, body composition assessment and morphological analysis reveals adipose atrophy and presence of smaller adipocytes. Fat loss is associated with reduced quality of life in cancer patients and shorter survival independent of body mass index. Fat loss occurs in both visceral and subcutaneous depots; however, the pattern of loss has been incompletely characterized. Increased lipolysis and fat oxidation, decreased lipogenesis, impaired lipid depositionand adipogenesis, as well as browning of white adipose tissue may underlie adipose atrophy in cancer. Inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1 beta (IL-1β) produced by the tumor or adipose tissue may also contribute to adipose depletion. Identifying the mechanisms and time course of fat mass changes in cancer may help identify individuals at risk of adipose depletion and define interventions to circumvent wasting. This review outlines current knowledge of fat mass in cancer and illustrates the need for further studies to assess alterations in visceral and subcutaneous adipose depots and possible mechanisms for loss of fat during cancer progression.http://www.mdpi.com/2072-6643/6/11/5280adipose tissuecancercomputed tomographyfat mobilization
collection DOAJ
language English
format Article
sources DOAJ
author Maryam Ebadi
Vera C. Mazurak
spellingShingle Maryam Ebadi
Vera C. Mazurak
Evidence and Mechanisms of Fat Depletion in Cancer
Nutrients
adipose tissue
cancer
computed tomography
fat mobilization
author_facet Maryam Ebadi
Vera C. Mazurak
author_sort Maryam Ebadi
title Evidence and Mechanisms of Fat Depletion in Cancer
title_short Evidence and Mechanisms of Fat Depletion in Cancer
title_full Evidence and Mechanisms of Fat Depletion in Cancer
title_fullStr Evidence and Mechanisms of Fat Depletion in Cancer
title_full_unstemmed Evidence and Mechanisms of Fat Depletion in Cancer
title_sort evidence and mechanisms of fat depletion in cancer
publisher MDPI AG
series Nutrients
issn 2072-6643
publishDate 2014-11-01
description The majority of cancer patients experience wasting characterized by muscle loss with or without fat loss. In human and animal models of cancer, body composition assessment and morphological analysis reveals adipose atrophy and presence of smaller adipocytes. Fat loss is associated with reduced quality of life in cancer patients and shorter survival independent of body mass index. Fat loss occurs in both visceral and subcutaneous depots; however, the pattern of loss has been incompletely characterized. Increased lipolysis and fat oxidation, decreased lipogenesis, impaired lipid depositionand adipogenesis, as well as browning of white adipose tissue may underlie adipose atrophy in cancer. Inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1 beta (IL-1β) produced by the tumor or adipose tissue may also contribute to adipose depletion. Identifying the mechanisms and time course of fat mass changes in cancer may help identify individuals at risk of adipose depletion and define interventions to circumvent wasting. This review outlines current knowledge of fat mass in cancer and illustrates the need for further studies to assess alterations in visceral and subcutaneous adipose depots and possible mechanisms for loss of fat during cancer progression.
topic adipose tissue
cancer
computed tomography
fat mobilization
url http://www.mdpi.com/2072-6643/6/11/5280
work_keys_str_mv AT maryamebadi evidenceandmechanismsoffatdepletionincancer
AT veracmazurak evidenceandmechanismsoffatdepletionincancer
_version_ 1725768505880477696